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CD8 T cells play an important role in controlling Ebola infection and in mediating vaccine-induced protective immunity, yet little is
known about antigenic targets in Ebola that are recognized by CD8 T cells. Overlapping peptides were used to identify major
histocompatibility complex class I-restricted epitopes in mice immunized with vectors encoding Ebola nucleoprotein (NP). CD8 T-cell
responses were mapped to a H-2d-restricted epitope (NP279–288) and two H-2b-restricted epitopes (NP44–52 and NP288–296). The
identification of these epitopes will facilitate studies of immune correlates of protection and the evaluation of vaccine strategies in murine
models of Ebola infection.
D 2003 Elsevier Inc. All rights reserved.Keywords: Ebola; CD8 T cells; MHC class I epitope; Vaccine; Heterologous prime/boostIntroduction
Ebola, a member of the filoviruses, causes severe hem-
orrhagic fever in humans and non-human primates. Four
distinct species have been identified, the most pathogenic of
which, Ebola Zaire, has a fatality rate of approximately 85%.
Throughout the previous 10 years, outbreaks of Ebola have
occurred regularly in several central African countries, such
as Gabon and Uganda (Arthur, 2002). Often, spread has
occurred through nosocomial inoculation including many
infections in primary care givers. In addition, the potential
use of Ebola for the purposes of bioterrorism highlights the
need for methods of rapidly controlling its spread and
protecting uninfected individuals, particularly in certain
sections of the population such as health workers. There
are currently no effective treatments or vaccines available for
Ebola. Recent studies, however, have shown the potential of
recombinant vaccination strategies to protect both small
animals and non-human primates from challenge with infec-
tious Ebola (Hart, 2003; Sullivan et al., 2000). Further
development of effective vaccines depends on understanding0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
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immunity and identifying protective antigens that are recog-
nized by these effector cells. A major impediment to the
study of T-cell responses against Ebola concerns the com-
plexities of applying immunological techniques to BSL-4
conditions. To overcome these difficulties, we have
employed a heterologous prime/boost strategy using recom-
binant vaccine vectors expressing Ebola proteins to induce
high levels of Ebola-specific T cells and screen for T-cell
epitopes using overlapping peptide libraries. Here, we report
our detailed mapping of H-2b- and H-2d-restricted CD8 T-
cell epitopes from Ebola nucleoprotein (NP) and a compar-
ative analysis of several heterologous prime/boost vaccine
strategies. These results provide critical information for
analyzing T-cell responses in murine models of infection
with mouse-adapted Ebola that has been used as the first step
in testing experimental Ebola vaccines.Results
Mapping of H-2d-restricted CD8 T-cell epitopes in Ebola
nucleoprotein
Alphavirus and DNA-based vaccines expressing NP
have been shown to be protective against Ebola challenge
in animal models (Pushko et al., 2001; Vanderzanden et al.,
1998; Wilson and Hart, 2001). Adoptive transfer of T-cell
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(Wilson and Hart, 2001).
To identify CD8 T-cell epitopes in Ebola NP, a DNA
prime with double heterologous boost strategy was initially
employed to maximize the likelihood of obtaining a strong
cellular immune response. BALB/c mice were primed with
DNA expressing Ebola Zaire Mayinga NP (DNA-NP),
followed by boosting with replication-deficient adenovirus
encoding NP (Ad-NP), and finally with recombinant Lis-
teria monocytogenes expressing NP (rLM-NP). Spleno-
cytes were harvested 7 days after the final immunization
and re-stimulated in vitro with pools of overlapping
peptides corresponding to NP, followed by intracellular
interferon g (IFN-g) staining (Fig. 1A). Of 24 peptide
pools screened, only pools #8 and #17, as well as a
positive control of the endogenous rLM specific epitope,
LLO91–99, showed specific stimulation of an IFN-g
response in CD8 T cells, while the remaining pools, asFig. 1. Identification of an H-2d-restricted epitope in Ebola NP. BALB/c mice wer
later with rLM-NP (A–C). (A) At day 7 after rLM boost, splenocytes were st
responding CD8 T cells were visualized by intracellular IFN-g staining. Two pools
by pool #7. Also included are a negative control without peptides and a positive c
positive pools were tested with splenocytes from immunized mice at day 15 after rL
scored positive, while other peptides such as NP96–111 were negative. (C) Nona
immunized mice at day 45 after rLM boost. A predicted H-2Kd epitope (NP279
BALB/c mice were immunized and boosted with DNA-NP and Ad-NP or with con
were stimulated with NP279–288 or a control peptide NP276–285. Numbers indi
carried out at day 7 (A), day 15 (B), and day 45 (C) after the last immunization,exemplified by pool #7, showed no response (Fig. 1A and
data not shown).
Peptides were arrayed (see Materials and methods) so that
each peptide was represented in only two pools, allowing
easy identification of the candidate peptide by cross-
referencing positives (Maecker et al., 2001; van der Most
et al., 2002). The common peptide between pools #8 and #17
is NP276–291 (EVNSFKAALSSLAAKHG) and this pep-
tide was able to stimulate a population of CD8 T cells from
immunized mice to produce IFN-g, while other individual
peptides from either pool #8 or #17, such as peptide NP96–
111, were not (Fig. 1B and data not shown). To finely map
the epitope within this peptide, the NP sequence was
analyzed using the SYFPEITHI algorithm (Rammensee et
al., 1999) to predict possible H2-Dd-, Kd-, or Ld-restricted
epitopes. A number of potential H-2d-restricted peptides
were predicted, but the only one of which to fall within
NP276–291 was NP279–288 (SFKAALSSLA). NP279–e immunized with DNA-NP, boosted 7 days later with rAd-NP, and 32 days
imulated in vitro with pools of overlapping peptides from Ebola NP and
(#8 and #17) scored positive while all others were negative as exemplified
ontrol with a known LM epitope LLO91–99. (B) Individual peptides from
M boost. The common peptide (NP276–291) present in both positive pools
mer peptides derived from NP276–291 were tested with splenocytes from
–288) tested positive while others (e.g. NP276–285) were negative. (D)
trol DNA-GFP and Ad-GFP. At day 21 after adenovirus boost, splenocytes
cate the percentage of CD8 T cells that produced IFN-g (Note: Assays were
which accounts for the different levels of the response.)
Fig. 2. Identification of H-2b-restricted epitopes in Ebola NP. C57BL/6
mice were immunized sequentially with DNA, 7 days later with AdNP, and
30 days later with rLM-NP. At day 7 after rLM immunization, splenocytes
were stimulated in vitro with peptides and responding CD8 T cells were
visualized by intracellular IFN-g staining. (A) Pools of overlapping
peptides from Ebola NP were tested and four pools (#6, #9, #13, and #19)
scored positive while all others were negative as exemplified by pool #3.
(B) Individual peptides from positive pools were tested and NP41–56 and
NP386–401 scored positive, while other peptides such as NP26–41 were
negative. (C) Nonamer peptides, NP44–52 and NP388–396, predicted to
be potential H-2Dk-restricted epitopes in NP41–56 and NP38–401,
respectively, tested positive while the NP393–410 and no peptide controls
were negative. Numbers indicate the percentage of CD8 T cells that
produced IFN-g.
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terminus of peptide #56 (NP276–285; EVNSFKAALS),
were synthesized and tested for their ability to stimulate
splenic CD8 T cells from immunized mice (Fig. 1C). The
nonamer peptide NP279–288 and the parental 16-mer pep-
tide NP276–291 were positive in inducing a population
(f4.5%) of CD8 T cells to produce IFN-g while the control
peptide, NP276–285, was not. Subsequent testing of
NP279–288 confirmed its role as a strong CD8 T-cell
epitope elicited by NP, but not control, immunizations
(Fig. 1D). A DNA-NP prime followed by an Ad-NP boost
was sufficient to stimulate a strong CD8 T-cell response to
NP279–288 while a control of DNA plasmid encoding GFP
followed by an Ad-GFP boost did not induce a NP279–288-
specific response (Fig. 1D). Mapping of the minimal epitope
of NP279–288 represents the first H-2d-restricted (and by
computational analysis Kd-restricted) peptide described for
Ebola NP.
Mapping of H-2b-restricted CD8 T-cell epitopes in Ebola
nucleoprotein
Using the same strategy, two H-2b-restricted epitopes
were identified in C57BL/6 mice (Fig. 2). C57BL/6 mice
were immunized in an identical fashion to the BALB/c
mice, with DNA-NP, Ad-NP, and rLM-NP inoculations.
Splenocytes were stimulated with peptide pools and positive
IFN-g T-cell responses were noted with peptide pools #6,
#9, #13, and #19 (Fig. 2A). Positive results in these four
peptide pools corresponded to four potential peptides
NP26–41, NP41–56, NP386–401, and NP401–416. While
NP26–41 and NP401–416 gave results similar to the no
peptide control, NP41–56 and NP386–401 were strongly
positive when tested in isolation (Fig. 2B). NP41–56 was a
shared peptide in pools #9 and #13, while NP386–401 was
contained in both pools #6 and #19. Thus, it was likely that
these peptides comprised two separate epitopes within NP.
Using SYFPEITHI (Rammensee et al., 1999), a H-2Db-
restricted epitope NP44–52 (YQVNNLEEI) was predicted
to be present within the NP41–56 sequence and this was
confirmed experimentally as the NP44–52 nonameric pep-
tide was able to stimulate IFN-g-producing CD8 T cells in
splenocytes from immunized mice (Fig. 2C). NP44–52
corresponds to a previously described H-2b epitope in NP,
NP43–53 (Wilson and Hart, 2001), although our result
further mapped this epitope to a minimal nonamer NP44–
52. Interestingly, no peptides within NP386–401 were
predicted to have strong binding affinity for H-2Kb or H-
2Db by the SYFPEITHI algorithm. Two peptides (NP388–
396 and NP393–402) within NP386–401, however, had a
low predicted binding affinity for H-2Db. NP388–396
(FQQTNAMVT) tested positive experimentally (Fig. 2C),
while the second peptide (AMVTLRKERL; NP393–402)
was negative in stimulating CD8 T cells from NP-immu-
nized mice (Fig. 2C). Thus, NP388–396 represents a novel
H-2b-restricted epitope in Ebola NP. NP43–53 gave astronger response than NP388–396 with approximately
8.5% and 2.2% of CD8 T cells responding to these peptides,
respectively (Fig. 2C). Also, in all assays using the 16-mer
peptides encompassing these epitopes (NP41–56 and
NP386–401, respectively), a stronger response to the
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represent the immunodominant epitope in NP-immunized
C57BL/6 mice.
Optimization of immunization strategies
Our initial strategy utilized a triple immunization proto-
col involving DNA-NP-prime/Ad-NP boost/rLM-NP boost
to facilitate generation of Ebola-specific T cells for identi-
fication of T-cell epitopes. We next tested various prime/Fig. 3. Comparison of various heterologous prime/boost regimens in inducing Eb
DNA, AdNP, or rLM-NP alone, or followed 3 weeks (A and C) or 1 week (B and D
NP279–288-specific memory CD8 T cells were measured by intracellular IFN-g st
indicating the percentage of CD8 T cells that produced IFN-g. Data in the bar grboost immunization strategies for inducing NP279–288-
specific CD8 T cells in BALB/c mice (Fig. 3). Single
immunizations with any of the three immunogens led to
poor T-cell responses (Fig. 3A). Homologous prime/boost
with Ad-NP or rLM-NP were less effective than heterolo-
gous prime/boost with these two vectors, presumably due to
immune responses against the vector during the boost
(Schneider et al., 1999). However, homologous prime/boost
with Ad-NP did induce a strong CD8 T-cell response that
was much higher than that by homologous prime/boost withola NP-specific memory CD8 T cells. BALB/c mice were immunized with
) later with AdNP or rLM-NP boosts. At day 21 after the last immunization,
aining. FACS plots (A and B) are from a representative mouse with numbers
aphs (C and D) are means and standard deviations from three mice/group.
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effective in boosting a DNA-NP prime but was effective in
boosting an Ad-NP prime, while Ad-NP was very effective
in boosting either a DNA-NP or rLM-NP prime. The highest
response came from heterologous prime with rLM-NP
followed by boost with Ad-NP.
In the above prime/boost regimens, the boosts were given
3 weeks after initial primes as it has been shown that resting
the immune system for an extended period allows for better
boost. Due to the nature of filovirus infection, however, a
long immunization protocol is not desirable because it is
unlikely that large populations will be immunized prophy-
lactically against Ebola. Rather, a short protocol for stimu-
lating fast and effective protective immunity is needed in
situations without pre-existing immunity to control the
spread of a rapidly developing epidemic or bioterror attack.
We thus tested heterologous prime/boost immunizations
with a shorter interval (1 week) to optimize the immuniza-
tion strategy in terms of rapidity (Fig. 3B). Boosting with
Ad-NP only 1 week after DNA-NP prime was sufficient to
stimulate a strong antiviral response to a level comparable to
those when boost was given more than 3 weeks after prime.
As seen before, boosting DNA-NP prime with rLM-NP was
not effective. On the other hand, quick prime/boost regi-
mens using the Ad-NP/rLM-NP or rLM-NP/Ad-NP were
effective although the responses were slightly lower than
those induced by immunizations with a 3-week interval. It
will be interesting to see if a DNA prime followed rapidly
by a single boost may be sufficient to stimulate some level
of protection in small animal models, and whether this short
time-frame regimen would also work at stimulating at least
CD8 T-cell responses in primates and human.Discussion
Ebola represents an emerging potential threat, both in
terms of sporadic epidemics and possible bioterrorism.
Currently no effective therapies or vaccines exist and
relatively little is know about the pathogenic nature of the
virus. In particular, it is not clear why the virus is so
pathogenic in many cases, yet asymptomatic in others
(Leroy et al., 2000, 2001), and whether this is due to
differences in the immune response to the virus, especially
CTL responses. To study more closely cellular immune
responses in animal models, MHC-restricted CD8 T-cell
epitopes need to be identified. In this study, we have
identified two novel epitopes, H-2b-restricted NP388-396
and H-2d-restricted NP279–288, confirmed a previously H-
2b-restricted NP43-53 epitope (Wilson and Hart, 2001) and
further mapped this epitope to a minimal NP44–52 non-
amer. NP338–396, NP44–52, and NP279–288 epitopes are
predicted, using the SYFPEITHI algorithm, to be presented
by H-2Db, H-2Db, and H-2Kd, respectively.
Examination of the Ebola NP sequences reveals that the
three epitopes are conserved between different strains ofEbola Zaire, including a mouse-adapted strain (Bray et al.,
1999). Thus, these epitopes will enable the further detailed
study of the CD8 T-cell response to Ebola infection in mice,
including potential perturbation of the immune response by
Ebola-encoded determinants. One of the most striking
aspects of Ebola pathology is immune suppression, includ-
ing lymphocyte depletion and suppression of T-cell prolif-
eration as well as an apparent lack of inflammatory
infiltrates in target organs (Geisbert et al., 2000). Humoral
immune responses can also be defective, with Ebola-specif-
ic IgG often entirely absent in patients in whom infection
proved fatal (Baize et al., 1999). Of particular interest are
the differences in immune responses between individuals
where infection results in either fatality or asymptomatic
infection (Leroy et al., 2000, 2001). At least one determi-
nant of this is likely to be VP35, which acts as a type I
interferon antagonist (Basler et al., 2000). Other viral
determinants, including the glycoprotein (GP) have also
been suggested to play a role in the perturbation of the
immune response, including the down-regulation of MHC
and accessory molecules (Simmons et al., 2002) and the
ability to bind to DC-SIGN on dendritic cells (Simmons et
al., 2003), thus potentially inhibiting DC-SIGN/ICAM-3-
mediated interactions between dendritic cells and T cells.
The ability to determine specific T-cell responses to Ebola in
mice using these epitopes will aid in the investigation of
such parameters of viral pathogenesis.
The studies in murine models represent a necessary first
step in the development of potential vaccine strategies that
can then be further tested in primates and humans. The
results of our study provide critical information for studying
immune correlates of protection and evaluating effectivity of
vaccine strategies in murine models of Ebola infection. The
methods described here for mapping and analysis of T-cell
responses directed against Ebola NP protein can also be
easily adapted to study other Ebola proteins and in other
species such as primates and humans.Materials and methods
Plasmids and vectors
Ebola Zaire Mayinga-derived NP (Sanchez et al., 1989)
was cloned in pAd-Track CMV (He et al., 1998) as a DNA
vaccine (DNA-NP). Plasmid DNA was purified using Qia-
gen megaprep kits for administration into animals. Recom-
binant adenovirus expressing NP and GFP from separate
CMV promoters (Ad-NP) was generated from pAd-Track
CMV/NP using homologous recombination in bacteria (He
et al., 1998), amplified in 293f cells and purified using
Adeno-X columns (BD Biosciences, San Jose, CA). Virus
was titered on 293T cells and numbers of green fluorescent
cells quantified by flow cytometry to estimate a green
fluorescent unit per milliliter (GFU/ml) titer. Controls ex-
pressing only GFP (Ad-GFP) were generated in the same
G. Simmons et al. / Virology 318 (2004) 224–230 229way. Recombinant L. monocytogenes (rLM) strains were
constructed as previously described in a wild-type strain
(10403S, Shen et al., 1998). Three strains were constructed
that express the C-terminal half of Ebola nucleoprotein (NP)
epitope (XFL601), the N-terminal half of Ebola NP
(XFL602), or the full length of Ebola NP (XFL603). The
rLM strains were greatly attenuated due to expression of
Ebola NP. A cocktail containing an equal mixture of
XFL601, XFL602, and XFL603 was used for immunization
(for clarity, the cocktail is referred to as rLM-NP).
Peptides
Peptides derived from the Ebola Zaire Mayinga NP
sequence were synthesized as 16-mers with 11-amino-acid
overlap with the preceding peptide (Mimotopes, Victoria,
Australia) and dissolved in DMSO at approximately 80 Ag/
ml. Pools of peptides containing 10–12 peptides at a final
concentration of 1 Ag/ml each were aliquoted such that each
peptide was represented twice and thus results could be
cross-referenced and individual peptides identified (Maecker
et al., 2001; van der Most et al., 2002). Shorter peptides
corresponding to potential epitopes were obtained from
Invitrogen (Carlsbad, CA) or Bio-Synthesis Inc. (Lewisville,
TX) and solubilized in DMSO (80 Ag/ml). Peptides were
used at 0.1 Ag/ml and DMSO concentrations were kept
below 0.1% (v/v) in all final assay mixtures.
Animal experiments
C57BL/6 and BALB/C mice (6–8 weeks old) were
purchased from the National Cancer Institute (Frederick,
MD). Mice were immunized with 100 Ag DNA plasmid
(DNA-NP or DNA-GFP) via bilateral injections of 50 Al into
the anterior tibial muscles, i.p. with 2  108 GFU Adeno-
virus (Ad-NP or Ad-GFP), and i.v. with rLM-NP (1  107
CFU for BALB/c and 1  108 CFU for C57BL/6 mice). All
mice were maintained in accordance with Institutional
Animal Care and Use Committee-approved protocols at
the University Laboratory Animal Resources of the Univer-
sity of Pennsylvania School of Medicine (Philadelphia, PA).
Intracellular IFN-c staining
Splenocytes were cultured at 37 jC for 5 h in RPMI 1640
supplemented with 50 U/ml recombinant human IL-2,
monensin (1 Al/ml), and with or without 1 AM synthetic
peptide. Cells were stained with mAbs a-CD8 PerCP (clone
53-6.7) and mAbsa-CD44 (clone IM7) or a-CD11a (LFA-1,
clone 2D7) in 1% BSA/PBS (w/v). Splenocytes were then
permeabilized with a Cytofix/Cytoperm kit, and stained
with mAba-IFN-g (clone XMG1.2) and a-TNF-a (clone
MP6-Xt22). After staining, cells were fixed with 2% para-
formaldehyde/PBS (w/v), and acquired with a FACSCalibur
flow cytometer (BD Biosciences). Data was analyzed using
Flow-Jo (Tree-Star, San Carlos, CA).Acknowledgments
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